Number and Phenotypes of Dendritic Cells in the Bronchial Mucosa of Asthmatics and Controls
A.V.H. Jayaratnam,S. Ying,Q. Meng,C. Corrigan
DOI: https://doi.org/10.1016/j.jaci.2005.12.956
IF: 14.29
2006-01-01
Journal of Allergy and Clinical Immunology
Abstract:RATIONALE: Dendritic cells (DC) regulate cytokine production by T cells at mucosal surfaces and have recently become identifiable in tissue sections by the development of phenotype specific antibodies against the markers BDCA-1/3 (expressed on myeloid DC) and BDCA-2/4 (plasmacytoid DC). As a prelude to investigating chemokine and other mediator expression by mucosal DC in asthma, we hypothesized that DC of all phenotypes are identifiable in the bronchial mucosa of asthmatics compared with controls, but their numbers differ.METHODS: We used immunohistochemistry with validated antibodies (anti-BDCA-1,2,3 and 4) and digital image analysis to measure the numbers of DC in the submucosa in sections of endobronchial biopsies from 9 asthmatics (mean FEV1 87 ± 9.44% predicted, age 21 - 59 years) and 9 controls (mean FEV1 95 ± 4.20% predicted, age 19 - 39 years).RESULTS: Mean (±SEM) numbers of cell/mm2 of submucosa expressing BDCA-1, 2,3,4 were 8.04 ± 3.03, 31.90 ± 11.98, 20.77 ± 5.77 and 26.71 ±10.64 respectively in the asthmatics and 45.97 ± 14.37, 28.43 ± 7.03, 49.87 ± 7.84 and 38.95 ± 11.57 in the controls. Mean total numbers of BDCA-3 and BDCA-1 positive cells were significantly lower in asthmatics when compared to controls, whereas those of BDCA-2 and BDCA-4 positive cells were statistically equivalent.CONCLUSIONS: DC of all four BDCA phenotypes can be identified in the bronchial mucosa of asthmatics and controls. There is selective depletion of myeloid cells in asthma. RATIONALE: Dendritic cells (DC) regulate cytokine production by T cells at mucosal surfaces and have recently become identifiable in tissue sections by the development of phenotype specific antibodies against the markers BDCA-1/3 (expressed on myeloid DC) and BDCA-2/4 (plasmacytoid DC). As a prelude to investigating chemokine and other mediator expression by mucosal DC in asthma, we hypothesized that DC of all phenotypes are identifiable in the bronchial mucosa of asthmatics compared with controls, but their numbers differ. METHODS: We used immunohistochemistry with validated antibodies (anti-BDCA-1,2,3 and 4) and digital image analysis to measure the numbers of DC in the submucosa in sections of endobronchial biopsies from 9 asthmatics (mean FEV1 87 ± 9.44% predicted, age 21 - 59 years) and 9 controls (mean FEV1 95 ± 4.20% predicted, age 19 - 39 years). RESULTS: Mean (±SEM) numbers of cell/mm2 of submucosa expressing BDCA-1, 2,3,4 were 8.04 ± 3.03, 31.90 ± 11.98, 20.77 ± 5.77 and 26.71 ±10.64 respectively in the asthmatics and 45.97 ± 14.37, 28.43 ± 7.03, 49.87 ± 7.84 and 38.95 ± 11.57 in the controls. Mean total numbers of BDCA-3 and BDCA-1 positive cells were significantly lower in asthmatics when compared to controls, whereas those of BDCA-2 and BDCA-4 positive cells were statistically equivalent. CONCLUSIONS: DC of all four BDCA phenotypes can be identified in the bronchial mucosa of asthmatics and controls. There is selective depletion of myeloid cells in asthma.